Bachmann K, Shapiro R, Mackiewicz J
J Clin Pharmacol. 1977 May-Jun;17(5-6):292-9. doi: 10.1002/j.1552-4604.1977.tb04608.x.
Plasma warfarin half-life was estimated in four patients with renal dysfunction and five normal control subjects. Hypoprothrombinemic responsiveness to a single oral dose of warfarin (0.75 mg/kg) was also evaluated for both groups. The mean warfarin half-life of 29.9+/-5.0 (S.E.M.) hours for renal patients was significantly shorter than the 44.8+/-6.0 hours half-life for normal controls (P less than 0.05). Additionally, a positive correlation was found between warfarin half-life and creatinine clearance. Pharmacologic responsiveness to warfarin was comparable for both groups. It therefore appears that patients with renal dysfunction do not possess an increased susceptibility, either pharmacokinetic or pharmacologic, to the hypoprothrombinemic effect of warfarin.
在4例肾功能不全患者和5例正常对照受试者中估计了血浆华法林半衰期。同时对两组患者口服单剂量华法林(0.75mg/kg)后的低凝血酶原血症反应性进行了评估。肾功能不全患者的平均华法林半衰期为29.9±5.0(标准误)小时,显著短于正常对照组的44.8±6.0小时半衰期(P<0.05)。此外,还发现华法林半衰期与肌酐清除率之间呈正相关。两组对华法林的药理反应性相当。因此,肾功能不全患者对华法林低凝血酶原血症作用在药代动力学或药理学方面似乎均没有更高的易感性。